Risk-Based Management of Follicular Lymphoma: Case 1
Risk-Based Management of Follicular Lymphoma
June 2015
A 75-year-old female presents to her physician with bilateral inguinal adenopathy. She is otherwise healthy.
- Laboratory findings: CBC count and LDH WNL
- CT scan shows scattered adenopathy in the pelvis, mesentery, retroperitoneal regions. The largest lymph node is 2.6 cm.
- Chest radiography, normal
- Bone marrow biopsy is negative
- Excisional biopsy, IHC staining for CD10 shows grade 1 follicular lymphoma
Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma
March 8th 2024Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
Read More
FDA Grants Priority Review to Epcoritamab for R/R Follicular Lymphoma
February 27th 2024If FDA-approved, epcoritamab would be the first and only subcutaneous bispecific antibody indicated for the treatment of adult patients with relapsed/refractory follicular lymphoma after 2 rounds of previous therapy.
Read More
Second-Line Liso-cel Shows Promise in High-Risk Relapsed/Refractory FL
January 12th 2024In an interview with Targeted Oncology, Franck Morschhauser, MD, PhD, discussed the high complete response rates and durable remissions seen with lisocabtagene maraleucel in patients with high-risk relapsed/refractory follicular lymphoma.
Read More
Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma
December 11th 2023Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.
Read More
